The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesICC: Use at a concentration of 1 µg/ml.
IP: Use at an assay dependent dilution (PMID 19224918).
WB: Use at a concentration of 0.5 - 2 µg/ml. Detects a band of approximately 65 kDa (predicted molecular weight: 65 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionBinds to the IL-1 type I receptor following IL-1 engagement, triggering intracellular signaling cascades leading to transcriptional up-regulation and mRNA stabilization.
Tissue specificityExpressed in spleen, thymus, prostate, lung, liver, skeletal muscle, kidney, pancreas and peripheral blood leukocytes.
Sequence similaritiesBelongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. Pelle subfamily. Contains 1 death domain. Contains 1 protein kinase domain.
DomainThe protein kinase domain is predicted to be catalytically inactive.
Anti-IRAK antibody (ab62419) reactivity with reduced wildtype (WT) or IRAK2 knockout (KO) mouse embryonic fibroblast (MEF) cell lysate. After SDS-PAGE, membranes were blocked in 5% milk for 1h at 25°C before incubation with ab62419 (1µg/ml dilution in 5% milk in TBS/0.5% Tween) for 16h at 4ºC. The blot was then incubated with an anti-Rabbit HRP-conjugated secondary antibody before developing with ECL.